The following blog post was provided by Peyton Myers, an undergraduate student at Appalachian State University. Myers attended the 2023 ISPE Annual Meeting & Expo in Las Vegas as an ISPE Foundation Professional Development Grant recipient.
According to the FDA, Quality by Design (QbD) is a “scientific, risk-based, holistic approach to pharmaceutical development” that involves a “deliberate design effort from product conception through commercialization.” Use of QbD in pharmaceutical manufacturing yields substantial business benefits, including:
In addition to these benefits, recent regulatory developments suggest a push toward QbD – for instance, the FDA recently suggested that all Abbreviated New Drug Applications (ANDAs) for generic drugs should have QbD elements. How can your company turn Quality by Design into a practical reality? ISPE’s QbD Training Course provides an in-depth explanation of product and process development using Quality by Design methods. Through group exercises, in-depth discussion, and real-life examples, you’ll learn how to effectively implement this manufacturing strategy. ISPE training courses are led by internationally recognized experts and carefully designed for you. Our course instructors deliver the kind of training that will yield visible results for you upon returning to work. By the end of our Quality by Design Course, you’ll be able to:
Interested in learning more about Quality by Design? ISPE’s next QbD course takes place 23 – 24 May in Tampa, Florida.
The following blog post was provided by Peyton Myers, an undergraduate student at Appalachian State University. Myers attended the 2023 ISPE Annual Meeting & Expo in Las Vegas as an ISPE Foundation Professional Development Grant recipient.
The integration of data science in biopharmaceutical manufacturing, emphasizing data quality, tech transfer efficiency, and process optimization, is the heart of this track. Led by industry experts, discussions explore leveraging digital twins, predictive analytics, and continuous improvement initiatives. Additionally, interactive roundtable discussions provide attendees with a dynamic forum...
The pharmaceutical sector stands at a crossroads of immense possibilities. We are witnessing an unprecedented surge in innovation, fueled by a remarkable partnership between industry and regulatory authorities. For example, there are initiatives fostered by the US Food and Drug Administration (US FDA) to promote innovation with programs such as CATT (CBER Advanced Technologies Team) and ETP...